NCT01812746View on ClinicalTrials.gov

A Phase 2 Study to Determine the Safety and Efficacy of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension), Administered to Patients With Metastatic Castration-Resistant Prostate Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

April 30, 2013

Primary Completion Date

April 30, 2016

Study Completion Date

April 30, 2016

Conditions
CRPCProstate Cancer
Interventions
DRUG

BIND-014

Trial Locations (8)

10065

Investigational Site #11, New York

27514

Investigational Site #15, Chapel Hill

33908

Investigative Site #17, Fort Meyers

37203

Investigational Site #18, Nashville

44195

Investigational Site #13, Cleveland

48109

Investigational Site #12, Ann Arbor

90048

Investigative Site #16, Los Angeles

94115

Investigative Site #14, San Francisco

Sponsors

Lead Sponsor

BIND Therapeutics
All Listed Sponsors
lead

BIND Therapeutics

INDUSTRY

NCT01812746 - A Phase 2 Study to Determine the Safety and Efficacy of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension), Administered to Patients With Metastatic Castration-Resistant Prostate Cancer | Biotech Hunter | Biotech Hunter